Study Reveals Mislabeling of Most Medical Marijuana Products Sold Online


Published Date : Nov 10, 2017

Researchers at the University of Pennsylvania have found that close to a 70.0% of cannabidiol (CBD) products available for online retail purchase are either under or over-labeled. The research team headed by adjunct assistant professor of psychology in psychiatry, Marcel Bonn-Miller had searched and identified CBD products that displayed CBD content on their packaging. 84 CBD products commercially made available by 31 different brands had been purchased and sent to an independent laboratory for the analysis of their ingredients with the help of high-performance liquid chromatography.

31.0% of the CBD products had been found to be accurate in terms of their CBD amount in comparison with that advertised on the label. However, 26.0% of the products contained more CBD than the amount advertised and 42.0% had been under-labeled. The term “accurate” in the study refers to CBD content within 10.0% of the advertised amount.

Unavailability of Quality Assurance Oversight from FDA Poses Bigger Problem

Researchers have discovered that the accurate labeling of the CBD products varied with respect to type of product. The discrepancy about the CBD amount could mean that patients buying the products have been consuming a higher dose than required or taking ineffective medicines. As frequent as 90.0% of the time, vaping liquid containing CBD has been mislabeled. Furthermore, alcohol extracts and tinctures have been likely to be over, under, or even accurately labeled. However, 50.0% of extract oils have been inaccurately labeled.

Bonn-Miller has been of the opinion that the rampant mislabeling of CBD products could be a direct effect of insufficient oversight or regulation. Currently, there have not been any standards for labeling, testing, and production of CBD extract oils.